{"transactions":[{"id":701343,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-30T01:36:56.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":15435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 15,435 shares of the Issuer's common stock, which vests in full on the earlier of (i) July 27, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments X, LP."}],"balance_after":15435,"derivative":{"exercise_price":28.56,"expiration_date":"2036-07-27","underlying":"Common Stock","underlying_shares":15435},"source":{"system":"sec-edgar","filing":"0001104659-26-088371","document":"tm2621459-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926088371/tm2621459-11_4seq1.xml","form_type":"4"}},{"id":737388,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:13:48.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":208333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5303908,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":208333},"source":{"system":"sec-edgar","filing":"0000947871-26-000626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000626/ownership.xml","form_type":"4"}},{"id":737387,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:13:48.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":1041667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":26519541,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1041667},"source":{"system":"sec-edgar","filing":"0000947871-26-000626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000626/ownership.xml","form_type":"4"}},{"id":744207,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744206,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744205,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5095575,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744204,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25477874,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":754009,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:06.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526254124/ownership.xml","form_type":"4"}},{"id":1051151,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3073298,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051150,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15366490,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051149,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":2022277,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2022277,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2022277},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051148,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":10111384,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10111384,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10111384},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051147,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":1051021,"price":0.8677,"value":911970.9217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1051021,"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051146,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":5255106,"price":0.8677,"value":4559855.4762,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5255106,"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051152,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-02T10:35:05.000Z","date":"2025-08-28","kind":"grant","planned":false,"acquired":true,"shares":66300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP."}],"balance_after":66300,"derivative":{"exercise_price":0.99,"expiration_date":"2035-08-28","underlying":"Common Stock","underlying_shares":66300},"source":{"system":"sec-edgar","filing":"0001193125-25-193328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525193328/ownership.xml","form_type":"4"}},{"id":1111853,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T21:10:06.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP."}],"balance_after":10000,"derivative":{"exercise_price":50.86,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-25-086362","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025086362/ownership.xml","form_type":"4"}},{"id":1191016,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:08:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":756,"price":54.11,"value":40907.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":186541,"source":{"system":"sec-edgar","filing":"0000947871-25-000346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000346/ownership.xml","form_type":"4"}},{"id":1191015,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:08:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":3026,"price":54.11,"value":163736.86,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":746171,"source":{"system":"sec-edgar","filing":"0000947871-25-000346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000346/ownership.xml","form_type":"4"}},{"id":1191014,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:08:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":1956,"price":54.11,"value":105839.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":482308,"source":{"system":"sec-edgar","filing":"0000947871-25-000346","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000346/ownership.xml","form_type":"4"}},{"id":1194710,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":1320,"price":54,"value":71280.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":187297,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194709,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":5279,"price":54,"value":285066.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisorsis the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":749197,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194708,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":3412,"price":54,"value":184248.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":484264,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194707,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":364,"price":54.01,"value":19659.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":188617,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194706,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":1457,"price":54.01,"value":78692.57,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisorsis the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":754476,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194705,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":941,"price":54.01,"value":50823.41,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":487676,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194704,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":5228,"price":54.02,"value":282416.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":188981,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194703,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":20911,"price":54.02,"value":1129612.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisorsis the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":755933,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1194702,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:03:14.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":13517,"price":54.02,"value":730188.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":488617,"source":{"system":"sec-edgar","filing":"0000947871-25-000334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000334/ownership.xml","form_type":"4"}},{"id":1209892,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":10733,"price":54.44,"value":584304.52,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":194209,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209891,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":42930,"price":54.44,"value":2337109.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":776844,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209890,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":27750,"price":54.44,"value":1510710.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":502134,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209889,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":233,"price":55.05,"value":12826.65,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":204942,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209888,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":933,"price":55.05,"value":51361.65,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":819774,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209887,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":603,"price":55.05,"value":33195.15,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":529884,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209886,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":3567,"price":54.01,"value":192653.67,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":205175,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209885,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":14267,"price":54.01,"value":770560.67,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":820707,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209884,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":9222,"price":54.01,"value":498080.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":530487,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209883,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":53,"price":55.01,"value":2915.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":208742,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209882,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":211,"price":55.01,"value":11607.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":834974,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209881,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":136,"price":55.01,"value":7481.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539709,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209880,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":26596,"price":54.29,"value":1443896.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":208795,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209879,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":106384,"price":54.29,"value":5775587.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":835185,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1209878,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:36:13.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":68766,"price":54.29,"value":3733306.14,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539845,"source":{"system":"sec-edgar","filing":"0000947871-25-000309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787125000309/ownership.xml","form_type":"4"}},{"id":1473325,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:27:54.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":10986,"price":36,"value":395496.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, GP VIII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":235391,"source":{"system":"sec-edgar","filing":"0000947871-24-000574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787124000574/ownership.xml","form_type":"4"}},{"id":1473324,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:27:54.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":43944,"price":36,"value":1581984.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, GP VIII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":941569,"source":{"system":"sec-edgar","filing":"0000947871-24-000574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787124000574/ownership.xml","form_type":"4"}},{"id":1473323,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:27:54.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":28404,"price":36,"value":1022544.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VI, GP VIII, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":608611,"source":{"system":"sec-edgar","filing":"0000947871-24-000574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787124000574/ownership.xml","form_type":"4"}},{"id":1479192,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:15:03.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP."}],"balance_after":10000,"derivative":{"exercise_price":38.85,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-24-073668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017024073668/ownership.xml","form_type":"4"}},{"id":1703435,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-20T23:16:19.000Z","date":"2023-12-18","kind":"exercise","planned":false,"acquired":false,"shares":1724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the exercise of stock options granted to Carl L. Gordon (\"Gordon\") on October 4, 2021 by Gemini Therapeutics, Inc. (\"Gemini\"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. (\"Disc\"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These stock options vested on October 4, 2022."}],"balance_after":0,"derivative":{"exercise_price":38,"expiration_date":"2031-10-03","underlying":"Common Stock","underlying_shares":1724},"source":{"system":"sec-edgar","filing":"0000947871-23-001167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001167/ownership.xml","form_type":"4"}},{"id":1703434,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-20T23:16:19.000Z","date":"2023-12-18","kind":"sale","planned":false,"acquired":false,"shares":1724,"price":59.24,"value":102129.76,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-23-001167","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001167/ownership.xml","form_type":"4"}},{"id":1703433,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-20T23:16:19.000Z","date":"2023-12-18","kind":"exercise","planned":false,"acquired":true,"shares":1724,"price":38,"value":65512.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the exercise of stock options granted to Carl L. Gordon (\"Gordon\") on October 4, 2021 by Gemini Therapeutics, Inc. (\"Gemini\"). On December 29, 2022, Gemstone Merger Sub, Inc., a wholly owned subsidiary of Gemini, merged with and into Disc Medicine Opco, Inc. (\"Disc\"), with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger. In connection with the merger, Disc changed its name to Disc Medicine, Inc. Gordon is a member of OrbiMed Advisors LLC (\"OrbiMed Advisors\") and was a member of Gemini's board of directors. Pursuant to an agreement with OrbiMed Advisors, Gordon assigned these stock options to OrbiMed Advisors."}],"balance_after":1724,"source":{"system":"sec-edgar","filing":"0000947871-23-001167","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001167/ownership.xml","form_type":"4"}},{"id":1709413,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T23:09:11.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":57100,"price":56.75,"value":3240425.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":224405,"source":{"system":"sec-edgar","filing":"0000947871-23-001155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001155/ownership.xml","form_type":"4"}},{"id":1709412,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T23:09:11.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":147600,"price":56.75,"value":8376300.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":580207,"source":{"system":"sec-edgar","filing":"0000947871-23-001155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001155/ownership.xml","form_type":"4"}},{"id":1709411,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T23:09:11.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":228500,"price":56.75,"value":12967375.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":897625,"source":{"system":"sec-edgar","filing":"0000947871-23-001155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001155/ownership.xml","form_type":"4"}},{"id":1711053,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":100,"price":57.73,"value":5773.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":727807,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711052,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-14","kind":"sale","planned":false,"acquired":false,"shares":100,"price":57.73,"value":5773.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1126125,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711051,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":14100,"price":58.56,"value":825696.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":281505,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711050,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":36400,"price":58.56,"value":2131584.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":727907,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711049,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":56200,"price":58.56,"value":3291072.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1126225,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711048,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":3600,"price":60.16,"value":216576.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":295605,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711047,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":9300,"price":60.16,"value":559488.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":764307,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1711046,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-14T22:40:00.000Z","date":"2023-12-12","kind":"sale","planned":false,"acquired":false,"shares":14400,"price":60.16,"value":866304.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1182425,"source":{"system":"sec-edgar","filing":"0000947871-23-001147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123001147/ownership.xml","form_type":"4"}},{"id":1860798,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T22:15:37.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":7136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP."}],"balance_after":7136,"derivative":{"exercise_price":45.69,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":7136},"source":{"system":"sec-edgar","filing":"0000899243-23-015262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924323015262/doc4.xml","form_type":"4"}},{"id":2007920,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-17T21:48:58.000Z","date":"2023-02-15","kind":"purchase","acquired":true,"shares":14329,"price":23,"value":329567.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were purchased in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":299205,"source":{"system":"sec-edgar","filing":"0000947871-23-000206","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123000206/ownership.xml","form_type":"4"}},{"id":2007919,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-17T21:48:58.000Z","date":"2023-02-15","kind":"purchase","acquired":true,"shares":37049,"price":23,"value":852127.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were purchased in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":773607,"source":{"system":"sec-edgar","filing":"0000947871-23-000206","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123000206/ownership.xml","form_type":"4"}},{"id":2007918,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-17T21:48:58.000Z","date":"2023-02-15","kind":"purchase","acquired":true,"shares":57318,"price":23,"value":1318314.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock were purchased in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP VIII, GP VI, or Genesis GP is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1196825,"source":{"system":"sec-edgar","filing":"0000947871-23-000206","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000094787123000206/ownership.xml","form_type":"4"}},{"id":2072810,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-04T02:23:18.000Z","date":"2022-12-29","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP."}],"balance_after":7000,"derivative":{"exercise_price":13.5,"expiration_date":"2032-12-28","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-23-000455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924323000455/doc4.xml","form_type":"4"}},{"id":2217023,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":170437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, (1) any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":170437},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217022,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":170437,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, (1) any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). Genesis GP is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":170437},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217021,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1136250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK (the \"Merger\"), the Company's outstanding warrants will be treated in accordance with their respective terms. At the effective time of the Merger, (1) any of the Company's outstanding Series A warrants will be cancelled and represent only the right to receive an amount in cash, without interest, equal to the Black Scholes Value (as defined in the Series A Warrants) which is calculated under the terms of the Series A warrants to be $45.98 per share of our common stock subject to the Series A warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2019-11-13","expiration_date":"2024-11-13","underlying":"Common Stock","underlying_shares":1136250},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217020,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option fully vested on June 8, 2022."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Pursuant to an agreement with OrbiMed Advisors and GP VII, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII."}],"balance_after":0,"derivative":{"exercise_price":18.11,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217019,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":6874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option fully vested on June 9, 2021."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Pursuant to an agreement with OrbiMed Advisors and GP VII, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII."}],"balance_after":0,"derivative":{"exercise_price":13.98,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":6874},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217018,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option fully vested on November 29, 2020."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Pursuant to an agreement with OrbiMed Advisors and GP VII, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII."}],"balance_after":0,"derivative":{"exercise_price":13.87,"expiration_date":"2029-11-29","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217017,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":226704,"price":55,"value":12468720.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217016,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":226704,"price":55,"value":12468720.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). Genesis GP is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2217015,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T16:46:16.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1511362,"price":55,"value":83124910.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, OrbiMed Genesis GP LLC (\"Genesis GP\"), and OrbiMed Capital LLC (\"OrbiMed Capital\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-040281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040281/doc4.xml","form_type":"4"}},{"id":2422364,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":56244,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Consists of Series B warrants previously held by Genesis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by the Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":56244},"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2422363,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":56244,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Consists of Series B warrants previously held by OPM."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by the Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":56244},"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2422362,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":false,"shares":374962,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Consists of Series B warrants previously held by OPI VII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date of the warrants is the date on the seventy-fifth (75th) day anniversary of the announcement by the Issuer, via publicly disseminated press release or SEC filing, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":13.2,"exercise_date":"2020-01-22","underlying":"Common Stock","underlying_shares":374962},"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2422361,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":56244,"price":13.2,"value":742420.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of the Reporting Person, OrbiMed Advisors, GP VII, Genesis GP, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":226704,"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2422360,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":56244,"price":13.2,"value":742420.8,"ownership":{"direct":false,"nature":"See footnotes (4),"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."}],"balance_after":226704,"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2422359,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-28T21:23:55.000Z","date":"2022-01-26","kind":"other","acquired":true,"shares":374962,"price":13.2,"value":4949498.4,"ownership":{"direct":false,"nature":"See footnotes (4),"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."}],"balance_after":1511362,"source":{"system":"sec-edgar","filing":"0001209191-22-005512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005512/doc4.xml","form_type":"4"}},{"id":2675422,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2021-06-09T10:36:58.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP."}],"balance_after":6000,"derivative":{"exercise_price":18.11,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-039091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919121039091/doc4.xml","form_type":"4"}},{"id":3114543,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-10T19:00:06.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":6874,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 8.333% of the total shares monthly, beginning on July 9, 2020, with 100% of the total shares vested and exercisable on June 9, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":6874,"derivative":{"exercise_price":13.98,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":6874},"source":{"system":"sec-edgar","filing":"0001209191-20-035688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919120035688/doc4.xml","form_type":"4"}},{"id":3296518,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T16:58:01.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":19500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,136,400 shares of Common Stock held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"), 170,460 shares of Common Stock held of record by OrbiMed Partners Master Fund Limited (\"OPM\") and 170,460 shares of Common Stock held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"), as adjusted for the Reverse Split. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors is the managing member of GP VII. OrbiMed Global Healthcare GP LLC (\"Healthcare GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Healthcare GP. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment manager of OPM and OrbiMed Capital is a relying advisor of OrbiMed Advisors. (Continued in footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VII and as a result may be deemed to have beneficial ownership of such securities; Healthcare GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities; and OrbiMed Capital may be deemed to have voting power and investment power over the securities held by OPM and as a result, may be deemed to have beneficial ownership over such securities. Each of GP VII, Healthcare GP, OrbiMed Advisors, OrbiMed Capital and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, Genesis or OPM, as applicable, except to the extent of its or her pecuniary interest therein, if any. The Reporting Person is an employee of OrbiMed Advisors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of 19,500 shares of Series A Preferred Stock which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split. Of the shares reported, 15,000 shares of Series A Preferred Stock are held of record by OPI VII, 2,250 shares of Series A Preferred Stock are held of record by Genesis, and 2,250 shares of Series A Preferred Stock are held of record by OPM."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1477320},"source":{"system":"sec-edgar","filing":"0001209191-20-005793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919120005793/doc4.xml","form_type":"4"}},{"id":3296517,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T16:58:01.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":1477320,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,136,400 shares of Common Stock held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"), 170,460 shares of Common Stock held of record by OrbiMed Partners Master Fund Limited (\"OPM\") and 170,460 shares of Common Stock held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"), as adjusted for the Reverse Split. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors is the managing member of GP VII. OrbiMed Global Healthcare GP LLC (\"Healthcare GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Healthcare GP. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment manager of OPM and OrbiMed Capital is a relying advisor of OrbiMed Advisors. (Continued in footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VII and as a result may be deemed to have beneficial ownership of such securities; Healthcare GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities; and OrbiMed Capital may be deemed to have voting power and investment power over the securities held by OPM and as a result, may be deemed to have beneficial ownership over such securities. Each of GP VII, Healthcare GP, OrbiMed Advisors, OrbiMed Capital and the Reporting Person disclaims beneficial ownership of the shares held by OPI VII, Genesis or OPM, as applicable, except to the extent of its or her pecuniary interest therein, if any. The Reporting Person is an employee of OrbiMed Advisors."}],"balance_after":1477320,"source":{"system":"sec-edgar","filing":"0001209191-20-005793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919120005793/doc4.xml","form_type":"4"}},{"id":3353916,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-03T16:15:47.000Z","date":"2019-11-29","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock options were granted on November 29, 2019 in connection with the Reporting Person's appointment to the Issuer's Board of Directors on November 22, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 8.333% of the total shares monthly, beginning on December 29, 2019, with 100% of the total shares vested and exercisable on November 29, 2020, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Person is an employee of OrbiMed Advisors LLC (\"OrbiMed Advisors\") and is obligated to transfer any shares issued pursuant to any equity grants made to her by the Issuer, or the economic benefits thereof, to OrbiMed Advisors and certain of its related entities. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":60000,"derivative":{"exercise_price":0.3467,"expiration_date":"2029-11-29","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-058690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919119058690/doc4.xml","form_type":"4"}}]}